Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased, driven mainly by direct sales, with new urology products performing particularly well. However, operating profit, ordinary profit and net income attributable to owners of the parent all declined due to the higher cost of sales ratio resulting from the weaker yen and increased expenses for developing new overseas markets.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥6,932 million (YoY +5.6%) |
| Operating profit | ¥336 million (YoY -38.6%) |
| Ordinary income | ¥398 million (YoY -24.2%) |
| Profit attributable to owners of the parent | ¥260 million (YoY -37.0%) |
| Net income per share | ¥31.63 |
| Equity ratio | End of the current fiscal period 81.9 / End of previous period 81.1 |
| Total assets | ¥20,140 million |
| Net assets | ¥16,489 million |
| Cash flows from operating activities | ¥494 million |
| Cash flows from investing activities | ¥-118 million |
| Cash flows from financing activities | ¥-680 million |
| Cash and cash equivalents at end of period | ¥4,936 million |
| Full-year earnings forecast | Net Sales ¥13,960 million (YoY +2.5%) / Operating profit ¥760 million (YoY -24.4%) / Ordinary income ¥800 million (YoY -19.0%) / Profit attributable to owners of the parent ¥560 million (YoY -21.5%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥13,960 million / Operating profit Not disclosed → ¥760 million / Ordinary income Not disclosed → ¥800 million / Profit attributable to owners of the parent Not disclosed → ¥560 million |
| Annual Dividend Forecast | 45 yen and sen → 47 yen and sen（+4.4%） |
| Depreciation and amortization | ¥308 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Subsidy Income ¥1,859 thousand / Extraordinary loss No |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 9,664,327 |
| Treasury Shares at Period-End | 1,647,294 |
| Factors Behind Changes in Business Performance | Net sales increased, driven mainly by direct sales, with new urology products performing particularly well. However, operating profit, ordinary profit and net income attributable to owners of the parent all declined due to the higher cost of sales ratio resulting from the weaker yen and increased expenses for developing new overseas markets. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased, driven mainly by direct sales, with new urology products performing particularly well. Profit declined because the weaker yen increased the cost of sales ratio and expenses for developing new overseas markets also rose.